GO43878: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Title
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Principal Investigator
Safi, Salah Ud Din
Phase
III
Age Group
Adult
Applicable Disease Sites
Lymphoma
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Syed Abdul Mannan Shah
Clinical Research Specialist
Phone: +1 304-293-1683
Email:

View on ClinicalTrials.gov